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Metabolic disorders, including obesity and insulin
resistance, have their basis in dysregulated lipid
metabolism and low-grade inflammation. In a micro-
array search of unique lipase-related genes whose
expressions are associated with obesity, we found
that two secreted phospholipase A2s (sPLA2s),
PLA2G5 and PLA2G2E, were robustly induced in
adipocytes of obese mice. Analyses of Pla2g5–/–
and Pla2g2e–/– mice revealed distinct roles of these
sPLA2s in diet-induced obesity. PLA2G5 hydrolyzed
phosphatidylcholine in fat-overladen low-density li-
poprotein to release unsaturated fatty acids, which
prevented palmitate-induced M1 macrophage polar-
ization. As such, PLA2G5 tipped the immune balance
toward an M2 state, thereby counteracting adipose
tissue inflammation, insulin resistance, hyperlipid-
emia, and obesity. PLA2G2E altered minor lipopro-
tein phospholipids, phosphatidylserine and phos-
phatidylethanolamine, and moderately facilitated
lipid accumulation in adipose tissue and liver. Collec-
tively, the identification of ‘‘metabolic sPLA2s’’ adds
this gene family to a growing list of lipolytic enzymes
that act as metabolic coordinators.
INTRODUCTION
Type 2 diabetes and metabolic syndrome are increasing at an
explosive rate worldwide due to a pandemic of obesity associ-
ated with insulin resistance, nonalcoholic fatty liver disease,
and hyperlipidemia (Despre´s and Lemieux, 2006). The mecha-nisms connecting obesity to insulin resistance include an
elevation of circulating lipids, ectopic lipid deposition leading
to lipotoxicity, and chronic inflammation in metabolically active
tissues (Hotamisligil, 2006). Obesity relies on dysregulations of
intracellular lipid metabolism or extracellular lipid partitioning
among tissues, and perturbation of intracellular/extracellular
lipases or related enzymes variably and often profoundly affect
obesity and insulin resistance (Chen et al., 2008; Chiu et al.,
2010; Haemmerle et al., 2006; Jaworski et al., 2009; Tian et al.,
2010; Wang et al., 2011).
Among the phospholipase A2 (PLA2) family, secreted PLA2s
(sPLA2s) have been implicated in inflammation and atheroscle-
rosis, since they can augment the production of proinflammatory
lipid mediators and hydrolyze phospholipids in lipoproteins to
generate proatherogenic particles in vitro (Murakami et al.,
2011). Recent genetic studies have revealed that individual
sPLA2s, which show distinct tissue distributions and substrate
preferences, participate in diverse biological events in response
to given microenvironmental cues (Sato et al., 2010; Taketomi
et al., 2013). However, the regulatory roles of sPLA2s in meta-
bolic disorders are not well understood. Except for studies
using sPLA2-overexpressing transgenic mice (Ivandic et al.,
1999; Sato et al., 2008), no reports have firmly established
whether sPLA2s could affect lipoprotein metabolism in vivo.
Moreover, although sPLA2s exert anti-inflammatory effects in
certain situations (Ait-Oufella et al., 2013; Miki et al., 2013),
except for PLA2G2D (group IID), a ‘‘resolving sPLA2’’ that ame-
liorates inflammation by mobilizing proresolving lipid mediators
(Miki et al., 2013), the molecular mechanisms for the anti-inflam-
matory actions of sPLA2s remain elusive.
In our efforts to search for particular lipase-related genes
whose roles in obesity have not been addressed before, we
found that two particular sPLA2s, PLA2G5 (group V) and
PLA2G2E (group IIE), were robustly induced in adipose tissue
of obese mice. Reportedly, PLA2G5 deficiency exacerbates orCell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc. 119
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unknown ways (Murakami et al., 2011). Notably, PLA2G5 gene
polymorphisms correlate with low-density lipoprotein (LDL)
levels in subjects with type 2 diabetes or obesity (Sergouniotis
et al., 2011; Wootton et al., 2007), and in vitro PLA2G5 suscep-
tibility of LDL from patients with type 2 diabetes is greater than
that of LDL from healthy subjects (Pettersson et al., 2008), sug-
gesting a role of this sPLA2 in metabolic regulation. After the
identification of PLA2G2E (Suzuki et al., 2000; Valentin et al.,
1999), its expression, target phospholipids, and biological
roles in vivo have remained a mystery for more than a decade.
We now provide evidence that the two diet-inducible, adipo-
cyte-driven ‘‘metabolic sPLA2s’’ play distinct roles in obesity,
hyperlipidemia, and insulin resistance, thus highlighting the
importance of the sPLA2 family in lipoprotein hydrolysis and
immune regulation in the process of metabolic disorders.
RESULTS
PLA2G5 and PLA2G2E Are Induced in Adipocytes of
Obese Mice
Weperformed gene profiling bymicroarray followed by quantita-
tive RT-PCR of perigonadal white adipose tissue (WAT) from
C57BL/6 mice fed a high-fat diet (HFD; 60% fat calorie) in com-
parison with those maintained on a low-fat diet (LFD; 4.8% fat
calorie) to identify particular lipase-related genes whose expres-
sion levels were altered by diets and whose functions in obesity
are currently unknown. We found that Pla2g5 and Pla2g2e, two
members of the sPLA2 family, were highly induced in the WAT
of HFD-fed mice compared with LFD-fed mice, ranking two of
the top three among the diet-inducible lipase-related genes (Fig-
ure 1A; Table S1, available online). Marked induction of these
two sPLA2s, but not other sPLA2s (Figure 1B) and intracellular
PLA2s (Figure S1A), in the WAT of HFD-fed mice was confirmed
by quantitative PCR. As in mice, the expression of PLA2G5 was
much higher than that ofmost other sPLA2s in humanmesenteric
WAT and fatty appendices, while that of PLA2G2E was very low
(Figure 1C; Table S2). Note that PLA2G2A,which is highly homol-
ogous to PLA2G2E (Suzuki et al., 2000; Valentin et al., 1999) and
absent in C57BL/6 mice due to a natural mutation (MacPhee
et al., 1995), was highly expressed in human WAT, suggesting
that PLA2G2E in mice might be compensated by PLA2G2A in
humans.
Among the tissues with high lipid demand, constitutive Pla2g5
expression in heart and skeletal muscle was unaffected by diet,
and its expression in WAT of HFD-fed mice exceeded that in any
other tissues examined so far and reached a level much higher
than that in bone marrow (BM)-derived denditic cells (BMDCs)
and macrophages (BMDMs) (Figure 1D). HFD-induced expres-
sion of Pla2g2e occurred robustly inWAT and brown adipose tis-
sue (BAT), while its expression in other tissues and cells was low
(Figure 1E). Moreover, WAT expression of both sPLA2s was far
greater in genetically obese Lepob/ob mice than in control mice
(Figure 1F). Kinetic experiments after HFD feeding revealed
robust induction of Pla2g5 and Pla2g2e in WAT by 8 weeks,
thereafter reaching a maximal plateau level (Figure S1A). The ki-
netic induction of Pla2g5 and Pla2g2e was similar to that of Lep,
which encodes leptin (Pelleymounter et al., 1995), but differed
from that of adipogenic or immune cell markers (Figure S1A).120 Cell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc.More detailed kinetic studies at an earlier period showed that
the HFD induction of Pla2g2e preceded that of Pla2g5 (Fig-
ure S1B). When the WAT was separated into adipocytes and
stromal vascular fraction (SVF), both sPLA2s were located pre-
dominantly in adipocytes of HFD-fedmice (Figures 1G and S1C).
Expression of Pla2g5 and Pla2g2e was increased markedly in
mouse 3T3-L1 preadipocytes after culture for 14 days with an
adipogenic cocktail (Figure S1D). Proinflammatory cytokines
failed to affect their expression in 3T3-L1 cells (Figure S1E).
Transwell culture of SVF cells and 3T3-L1 cells did not affect
or even decreased the expression of Pla2g5 and Pla2g2e, while
it increased that of Tnf and Ccl2, in the latter cells (Figure S1F),
ruling out the contribution of SVF-derived soluble factors to the
induction of these sPLA2s in adipocytes. Notably, Pla2g5, not
Pla2g2e, expression in differentiated 3T3-L1 cells was further
increased by the endoplasmic reticulum (ER) stress inducer
thapsigargin (Figure S1D) or tunicamycin (data not shown).
These results suggest that the inducible expression of Pla2g5
depends on the adipogenic program plus obesity-associated
ER stress (Ozcan et al., 2006), while adipogenesis is sufficient
to drive Pla2g2e expression. During adipogenesis, Pla2g2e
expression started to increase on day 3, lagging behind the
induction of the adipogenic marker Pparg, and continued to
increase by day 12 (Figure S1G).
Increased Diet-Induced Obesity in Pla2g5–/– Mice
To elucidate the role of PLA2G5 in obesity, we placed Pla2g5–/–
mice (Satake et al., 2004) and wild-type (WT) littermates on a
HFD, along with a control group of each genotype on a LFD.
HFD-induced obesity and weight gain were greater in Pla2g5–/–
mice than in Pla2g5+/+ mice (Figures 2A and 2B). Immunohisto-
chemistry confirmed the location of PLA2G5 protein in adipo-
cytes of HFD-fed WT mice, whereas hardly any such reactivity
was seen in those of Pla2g5–/– mice, which lacked Pla2g5
expression (Figures S2A and S2B). Computed tomography
(CT) showed significant increases in total, visceral, and subcu-
taneous fat depositions in HFD-fed Pla2g5–/– mice relative to
Pla2g5+/+ mice (Figure 2C). In agreement, the HFD-induced in-
crease in plasma leptin, whose expression correlates with
adiposity (Pelleymounter et al., 1995), was higher in Pla2g5–/–
mice than in Pla2g5+/+ mice (Figure 2D). Although daily food
intake was the same for both groups, locomotion and oxygen
consumption were lower in Pla2g5–/– mice (Figures S2C–S2E),
indicating decreased energy expenditure. The respiratory quo-
tient was unchanged in Pla2g5–/– mice (Figure S2F).
HFD-induced elevation of plasma insulin was greater in
Pla2g5–/– mice than in Pla2g5+/+ mice (Figure 2E), despite com-
parable hyperglycemia in both genotypes (Figure S2G), suggest-
ing exacerbated insulin resistance in Pla2g5–/– mice. Indeed,
on an insulin tolerance test (ITT), HFD-fed Pla2g5–/– mice had
greater insulin resistance than Pla2g5+/+ mice (Figure 2F). Insu-
lin-stimulated Akt phosphorylation was lower in WAT, but
not in skeletal muscle and liver, of Pla2g5–/– mice than in that
of Pla2g5+/+ mice (Figures 2G and S2H), suggesting that
Pla2g5 ablation decreases insulin sensitivity mainly in WAT,
where PLA2G5 is induced. In a glucose tolerance test (GTT),
the glucose disposal was similar in both genotypes (Figure 2H),
probably because glucose-stimulated insulin secretion was
greater in Pla2g5–/– mice than in Pla2g5+/+ mice (Figure 2I).
Figure 1. Obesity-Induced Expression of Pla2g5 and Pla2g2e in Hypertrophic Adipocytes
(A) Microarray of lipase-related genes in the WAT of C57BL/6 mice fed a LFD or HFD for 18 weeks. Values indicate fold increases in the HFD group relative to the
LFD group (n = 4; mean ± SD).
(B) Expression of sPLA2 mRNAs relative to Rn18s in the WAT of C57BL/6 mice fed a LFD (n = 6) or HFD (n = 9).
(C) Expression of sPLA2 mRNAs relative to RN18S in human visceral WAT (n = 18).
(D and E) Expression of Pla2g5 (D) and Pla2g2e (E) in various tissues and cells of C57BL/6 mice (n = 5).
(F) Expression of Pla2g5 and Pla2g2e in WAT of 12-week-old Lepob/ob mice, the expression in age-matched C57BL/6 mice being regarded as 1 (n = 3).
(G) Pla2g5 and Pla2g2e expression in adipocytes and SVF from WAT of LFD- or HFD-fed mice, the expression in adipocytes from LFD-fed mice being regarded
as 1 (n = 8).
In (B), (D), (E), and (G), mice were fed a LFD or HFD for 26weeks. Data are compiled from one (A, C, and F) or two (B, D, E, and G) experiments. Mean ± SEM (B–G),
*p < 0.05, **p < 0.01.
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oxygen consumption was unaffected, in Pla2g5/ mice at
6 weeks after HFD feeding (Figures S2I and S2J), indicating
that the metabolic dysfunction occurred prior to the decreased
energy expenditure.
HFD feeding led to greater adipocyte hypertrophy in WAT
(Figure 2J) and BAT (Figure S3A) of Pla2g5–/– mice compared
to those of WT mice, although expression levels of adipogenic,
lipogenic, lipid uptake, lipolytic, or thermogenic genes in WAT
(Figure 2K) and BAT (Figure S3B) were similar between the ge-
notypes. Expression of several other PLA2s, which have been
implicated in adiposity (Su et al., 2004), in WAT was unaffected
by PLA2G5 deficiency (Figure S3C). Thus, the increased obesity
in Pla2g5–/– mice may not arise from intrinsic alterations in theseadipocyte programs but may involve other extrinsic mecha-
nisms. HFD-increased plasma alanine aminotransferase (ALT)
level (Figure 2L) and hepatic fat deposition (Figures 2M
and 2N) were greater in Pla2g5–/– mice compared to Pla2g5+/+
mice. Consistently, hepatic expression of genes for lipid synthe-
sis or uptake and inflammation, but not for b-oxidation, was
increased in HFD-fed Pla2g5–/– mice over Pla2g5+/+ mice (Fig-
ures S3D and S3E), indicating exacerbated hepatic steatosis
in Pla2g5–/– mice. Since the expression of Pla2g5 in BAT
and liver was low (Figure 1D), and since visceral adiposity and
hepatic steatosis are etiologically intertwined (Despre´s and
Lemieux, 2006), the abnormalities in these tissues may reflect
a secondary effect resulting from the increased obesity in
Pla2g5–/– mice.Cell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc. 121
Figure 2. Increased Diet-Induced Obesity in Pla2g5–/– Mice
(A) Representative photos of Pla2g5+/+ and Pla2g5–/– mice fed a LFD or HFD for 14 weeks.
(B) Body weights of Pla2g5+/+ and Pla2g5–/– mice placed on a LFD or HFD for the indicated periods.
(C) CT analysis of fat volumes in Pla2g5+/+ and Pla2g5–/– mice. Yellow areas indicate fat deposition in HFD-fed mice (inset).
(D and E) Levels of fasting plasma leptin (D) and insulin (E) in Pla2g5+/+ and Pla2g5–/– mice.
(F) ITT using 6 hr fasted Pla2g5+/+ and Pla2g5–/– mice.
(G) Immunoblotting of phosphorylated (P-) and total Akt in WAT of HFD-fed Pla2g5+/+ and Pla2g5–/– mice with (+) or without () 5 min treatment with insulin. The
ratios of P-Akt to Akt were determined by densitometry, with the value of insulin-untreated Pla2g5+/+ mice being regarded as 1 (n = 4).
(legend continued on next page)
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Metabolic sPLA2s in ObesityAltered Lipoprotein Profiles in HFD-Fed Pla2g5–/– Mice
PLA2G5 hydrolyzes phosphatidylcholine (PC) in LDL and, to a
lesser extent, in high-density lipoprotein (HDL) in vitro (Sato
et al., 2008), yet in vivo evidence for this action was lacking.
Kinetically, HFD feeding was accompanied by increases of
phospholipids in plasma and in lipoproteins (Figure S4A), which
preceded Pla2g5 induction in WAT (Figure S1A). Plasma phos-
pholipid and cholesterol levels were significantly greater in
HFD-fed Pla2g5–/– mice than in Pla2g5+/+ mice (Figure 3A).
Moreover, phospholipid, cholesterol, and TG levels in LDL, but
not chylomicron (CM), very-low-density lipoprotein (VLDL), and
HDL, were significantly higher in HFD-fed Pla2g5–/– mice than
in Pla2g5+/+ mice (Figures 3B–3D, S4B, and S4C). These results
suggest that diet-induced PLA2G5 acts on LDL phospholipids,
eventually altering LDL lipid composition.
To explore the hydrolysis of LDL phospholipids by PLA2G5
further, phospholipids in LDL from HFD-fed mice were analyzed
by electrospray ionization mass spectrometry (ESI-MS). LDL in
HFD-fed Pla2g5–/– mice contained more PC34:1 (sn-1 palmitic
acid [PA; 16:0] and sn-2 oleic acid [OA; 18:1])—and, to a lesser
extent, other PC species containing polyunsaturated fatty acids
(PUFAs), such as PC34:2 (16:0 and linoleic acid [LA; 18:2]),
PC36:3 (18:1 and 18:2), PC36:4 (16:0 and arachidonic acid
[AA; 20:4]), and PC38:6 (16:0 and docosahexaenoic acid
[DHA, 22:6])—than that in Pla2g5+/+ mice (Figures 3E and
S4D). By contrast, PLA2G5 deficiency did not affect minor
LDL phospholipids, phosphatidylethanolamine (PE), and phos-
phatidylserine (PS) (Figure 3E). These results imply that
PLA2G5 preferentially hydrolyzes PC species (particularly those
containing a fatty acid with a lower degree of unsaturation, such
as OA in preference to LA [OA > LA]) in hyperlipidemic LDL
in vivo, a view that agrees with its substrate preference
in vitro (Pruzanski et al., 2005; Sato et al., 2008). Plasma levels
of nonesterified fatty acids (NEFA) and lysophosphatidylcholine
(LPC), which are PLA2 reaction products, did not differ in both
genotypes (Figure S4E), probably because the PLA2G5-driven
NEFA and LPC pools were small relative to their high back-
ground levels or because they were produced locally in WAT.
In support of the latter idea, the WAT level of OA was elevated
in Pla2g5+/+ mice after HFD feeding, whereas this increase was
not seen in Pla2g5/ mice (Figure 3F). PUFAs (LA > AA > DHA)
also tended to be lower in HFD-fed Pla2g5/ mice than in
Pla2g5+/+ mice, though to a lesser extent than OA. Overall,
these lipid profiles agree with the fatty acid preference of
PLA2G5. Thus, diet-induced PLA2G5 hydrolyzes PC in fat-over-
laden LDL to provide OA in preference to PUFAs in WAT, which
may eventually contribute to LDL lipid normalization. Notably,
as in mice, WAT expression levels of PLA2G5 showed a signif-
icantly inverse correlation with plasma LDL levels in humans(H) GTT using 16 hr fasted Pla2g5+/+ and Pla2g5–/– mice.
(I) Glucose-stimulated insulin secretion under the conditions in (H).
(J) Hematoxylin and eosin staining of WAT in Pla2g5+/+ and Pla2g5–/– mice (scale
(K) Expression of adipogenic, lipogenic, and lipolytic genes normalized by Gap
Pla2g5+/+ mice being regarded as 1.
(L and M) Levels of plasma ALT (L) and hepatic TG (M) in Pla2g5+/+ and Pla2g5–/
(N) Hematoxylin and eosin staining of liver from Pla2g5+/+ and Pla2g5–/– mice (sc
In (C)–(N), mice were fed a LFD or HFD for 26 weeks. Data are compiled from two (
are representative of two experiments. Mean ± SEM; *p < 0.05, **p < 0.01.(Figure 3G; Table S2), revealing an enzyme-substrate relation-
ship across species.
Exacerbated Adipose Tissue Inflammation in HFD-Fed
Pla2g5–/– Mice
Crown-like structures, an indication of macrophage infiltration,
were histologically greater in the WAT of HFD-fed Pla2g5–/–
than in that of Pla2g5+/+ mice (Figure 2J). Consistently, HFD-
induced WAT expression of M1 macrophage markers was
increased, whereas M2 macrophage markers were unchanged
or decreased, by Pla2g5 deficiency, allowing the M1/M2 ratio
to be greater in HFD-fed Pla2g5–/– mice (Figures 4A and 4B).
Flow cytometry confirmed that the WAT of HFD-fed Pla2g5–/–
mice contained a greater proportion of F40/80+CD11b+ macro-
phages, with a greater number of CD11c+ M1 and fewer
CD206+ M2 macrophages, compared to the WAT of Pla2g5+/+
mice (Figures 4C and 4D). Thus, PLA2G5 plays an anti-inflamma-
tory role in adipose tissue inflammation.
Recruitment of macrophages into obeseWAT relies on several
mechanisms, among which adipocyte death due to lipotoxicity
represents a driving factor, attracting macrophages for phago-
cytic clearance of dead cells (Cinti et al., 2005). As Pla2g5–/–
mice display lower macrophage phagocytosis (Balestrieri et al.,
2009; Boilard et al., 2010), we evaluated dead cells in Pla2g5–/–
or Pla2g5+/+ WAT. TUNEL staining revealed a marked increase
of dead cells in WAT of HFD-fed Pla2g5–/– mice over Pla2g5+/+
mice (Figures 4E and 4F). Thus, the reduced clearance of
dead cells by macrophages may account, at least partly, for
the increased inflammation in Pla2g5–/– WAT.
PLA2G5 Integrates Lipoprotein Metabolism and Anti-
Inflammation
Given that sPLA2 acts in a paracrine fashion, we speculated that
PLA2G5 secreted from adipocytes affected the properties of
macrophages. Addition of PLA2G5 to lipopolysaccharide and
interferon g (LPS+IFN-g)-stimulated BMDMs augmented the
expression of the M2 marker Arg1 without affecting that of the
M1markerNos2 (Figure 5A), suggesting that PLA2G5 selectively
upregulates the M2 gene. In a setting physiologically more rele-
vant to sterile inflammation in obesity, exposure of BMDMs to
PA, a saturated fatty acid that elicits proinflammatory responses
through Toll-like receptor 4 (TLR4) or ER stress (Hotamisligil,
2006), increased Nos2, did not affect Arg1, and decreased
Cd206, indicative of M1 skewing (Figures 5B and 5C). Further
addition of PLA2G5 to PA-treated BMDMs reduced Nos2, upre-
gulated Arg1, and partially restored Cd206 expression (Fig-
ure 5B). Pla2g5 expression was increased in PA-treated BMDMs
(Figure 5D), in line with its induction by ER stress in adipocytes
(Figure S1D). However, culture of Pla2g5+/+ and Pla2g5–/–bar, 50 mm).
dh in WAT of HFD-fed Pla2g5+/+ and Pla2g5–/– mice, with the expression in
– mice.
ale bar, 50 mm).
C, G, and I) or three (B, D–F, H, and K–M) experiments. Images in (A), (J), and (N)
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Figure 3. Altered Lipoprotein Profiles in HFD-Fed Pla2g5–/– Mice
(A) Plasma phospholipids (PL) and cholesterol (Chol) levels in Pla2g5+/+ and Pla2g5–/– mice (n = 4).
(B) PL and Chol levels in LDL and HDL from Pla2g5+/+ and Pla2g5–/– mice (n = 4).
(C) TG levels in individual lipoprotein particles from HFD-fed Pla2g5+/+ and Pla2g5–/– mice (n = 4).
(D) High-performance liquid chromatography (HPLC) profiles of PL, Chol, and TG in plasma lipoproteins from HFD-fed Pla2g5+/+ and Pla2g5–/– mice. Two
examples from each genotype are shown.
(E) ESI-MS of PC, PE, and PS in LDL from HFD-fed Pla2g5+/+ and Pla2g5–/– mice.
(F) ESI-MS of unsaturated fatty acids in WAT of Pla2g5+/+ and Pla2g5–/– mice.
(G) Correlation of PLA2G5 expression levels in human visceral WAT with LDL or HDL cholesterol (n = 128, 64 from mesentric WAT and 64 from colorectal fat
appendices).
In (A)–(F), mice were fed a LFD or HFD for 26 weeks. Data are representative of (A–C) or compiled from (D–G) two experiments. Mean ± SEM; *p < 0.05, **p < 0.01.
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duction of respective macrophage subset markers (Figure S5A),
suggesting that although PLA2G5 expressed at a low level in
macrophages is insufficient to affect their polarization, it can
facilitate the conversion of M1 to M2 macrophages when
supplied abundantly through a paracrine route. Indeed, when
irradiated WT mice were adoptively transferred with Pla2g5–/–
or Pla2g5+/+ BM cells, HFD-induced obesity, insulin resistance,
and hyperlipidemia were comparable in both groups (Figures
S5B–S5D). Thus, PLA2G5 in nonhematopoietic cells (likely adi-
pocytes) appears to be mainly responsible for the amelioration
of metabolic disorders.
Of the potential PLA2G5-driven lipid mediators tested, prosta-
glandin E2 (PGE2), an AA metabolite, had the ability to induce
Arg1, without affecting Nos2, in BMDMs stimulated with
LPS+IFN-g (Figure 5E) or PA (Figure 5F). Exogenous PLA2G5124 Cell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc.augmented PGE2 generation by PA-stimulated BMDMs (Fig-
ure 5G). In vivo, however, theWAT level of PGE2 did not differ be-
tween HFD-fed Pla2g5–/– and Pla2g5+/+ mice, while that of PGD2
was higher in the null mice, likely due to upregulation of PGD2
synthase (Figures S5E and S5F). Thus, it is more likely that
PLA2G5 action involves an alternative lipid-mediated process.
Proinflammatory ER stress induced by saturated fatty acids
can be ameliorated by unsaturated fatty acids (Hotamisligil,
2006). As PLA2G5 released OA > LA from LDL-PC (Figures 3D
and 3E), we examined whether these unsaturated fatty acids
affected PA-induced M1 macrophage polarization. Strikingly,
OA or LA canceled out the induction of Nos2 even at 2 mM and
also restored the expression of Cd206 dose dependently in
PA-treated BMDMs (Figure 5H). The WAT level of the PLA2G5-
sensitive OA pool was within a range enough to affect macro-
phage polarization (Figures 3E and 5H). Thus, OA, and possibly
Figure 4. Exacerbated Adipose Tissue Inflammation in HFD-Fed Pla2g5–/– Mice
(A) Expression of M1 or M2macrophage markers normalized byGapdh in WAT of Pla2g5+/+ and Pla2g5–/– mice, with their expression in Pla2g5+/+mice on a LFD
being regarded as 1.
(B) Ratios of M1 (Tnf) to M2 (Cd163) genes.
(C) FACS analysis of adipose tissue macrophages (ATM) from Pla2g5+/+ and Pla2g5–/– mice. Counts of F4/80+CD11b+ ATM and proportions of CD11chi (M1) and
CD206hi (M2) macrophages in SVF from WAT (n = 4).
(D) Representative FACS profiles of CD11c+ cells in the SVF.
(E and F) TUNEL staining of WAT in Pla2g5+/+ and Pla2g5–/– mice. Average scores of TUNEL-positive cells (E) and representative images (scale bar, 50 mm) (F).
Micewere fedaLFDorHFD for 26weeks.Data are compiled from (A,B, andE) or representative of (C,D, andF) twoexperiments.Mean±SEM; *p<0.05, **p<0.01.
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tion fromM1 toM2macrophages by attenuating the PA-induced
stress response, which underscores a mechanistic link between
PLA2G5-driven LDL hydrolysis and anti-inflammation in WAT.
PLA2G5 Is a Th2/M2-Prone sPLA2
While T helper 2 (Th2) cytokines are proallergic, they facilitate M2
macrophage polarization, thereby counteracting adipose tissue
inflammation and insulin resistance (Odegaard and Chawla,
2013). It has been shown that PLA2G5 from both hematopoietic
and nonhematopoietic origins regulates the Th2 response and
thereby asthma (Giannattasio et al., 2010; Henderson et al.,
2013). Indeed, when WT mice were immunized intraperitoneally
with ovalbumin (OVA), lymph node cells from Pla2g5–/– mice ex-
pressed levels of IL-4 and IL-13 lower than those from Pla2g5+/+
mice upon OVA challenge ex vivo (Figure S5G). Serum levels of
total or OVA-specific immunoglobulin E (IgE) were lower in
Pla2g5–/– mice than in Pla2g5+/+ mice (Figure S5H). Moreover,
beyond the crucial role of adipocyte- rather than macrophage-
derived PLA2G5 in obesity, Pla2g5 expression in BMDMs wasmarkedly induced by M2-skewing Th2 cytokines (IL-4 and IL-
13) and was unaffected or reduced byM1-skewing TLR agonists
(LPS and zymozan) or Th1 cytokines (IFN-g and granulocyte-
macrophage colony-stimulating factor [GM-CSF]) among others
(Figures S5I and S5J). In ex vivo skewing culture of splenic naive
CD4+ T cells, Pla2g5 was induced preferentially in IL-4-driven
Th2 cells (Figure S5K). In the context of obesity, theWAT expres-
sion of Il33, a stromal Th2 cytokine that increases M2 macro-
phages and suppresses adipose tissue inflammation (Miller
et al., 2010), was lower in HFD-fed Pla2g5–/– mice than in repli-
cate Pla2g5+/+ mice (Figure 5I). Thus, PLA2G5 is a unique
sPLA2 that is induced by Th2 cytokines and facilitates the Th2
and M2 responses. Pla2g5/ mice are Th2/M2 insufficient,
and this intrinsic immune balance shift may also underlie the
exacerbated adipose tissue inflammation.
Reduced Adiposity in Adipocyte-Specific Pla2g5
Transgenic Mice
To explore whether the forced overexpression of PLA2G5
in the WAT would yield outcomes opposite to its deletion, weCell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc. 125
Figure 5. PLA2G5 Promotes M2 Macrophage Polarization
(A and B) Expression ofM1 andM2macrophagemarkers inWTBMDMs cultured for 24 hr with (+) or without () LPS+IFN-g (A) or 200 mMPA (B) in the presence or
absence of 70 nM PLA2G5 (n = 7).
(C) Expression of M1 and M2 macrophage markers in WT BMDMs after culture for 24 hr with various concentrations of PA (n = 6).
(D) Expression of Pla2g5 in Pla2g5+/+ and Pla2g5–/– BMDMs after culture for 24 hr with 200 mM PA (n = 6).
(E and F) Expression of M1 andM2markers in WT BMDMs cultured for 24 hr with (+) or without () LPS+IFN-g (D) or 200 mMPA (E) in the presence or absence of
1 mM lipid mediators (n = 6).
(G) PGE2 generation by WT BMDMs treated for 6 hr with PLA2G5 in the presence (+) or absence () of 200 mM PA (n = 3).
(H) Effects of OA or LA on the expression of M1 or M2 macrophage markers in WT BMDMs treated for 24 hr with 200 mM PA (n = 3).
(I) Expression of Il33 relative to Gapdh in WAT of Pla2g5+/+ and Pla2g5–/– mice fed a LFD or HFD for 26 weeks.
Data are compiled from (A–F and I) or representative of (G and H) two experiments. Mean ± SEM; *p < 0.05, **p < 0.01.
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Pla2g5tg/+) by mating LNL-Pla2g5tg/+ mice (Ohtsuki et al.,
2006), in which the Pla2g5 transgene was silent, with Fabp4-
Cretg/+ mice, in which Cre recombinase is expressed under
control of the adipocyte-specific Fabp4 promoter (Figure S6A).
Fabp4-Pla2g5tg/+ mice were born normally and grew to adult-
hood. As expected, expression of Pla2g5 was robustly
increased in perigonadal WAT, but not in other tissues, in
Fabp4-Pla2g5tg/+ mice compared to control LNL-Pla2g5tg/+
mice (Figure S6B). Even on a LFD, where the influence of
diet-inducible endogenous PLA2G5 is negligible, Fabp4-
Pla2g5tg/+ mice had body weight significantly lower than that
of age-matched control mice (Figure S6C). CT scanning re-126 Cell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc.vealed a reduced adiposity in Fabp4-Pla2g5tg/+ mice relative
to control mice (Figure S6D). Phospholipid levels in plasma
and LDL were significantly lower in Fabp4-Pla2g5tg/+ mice
than in control mice (Figure S6E). Moreover, WAT expression
levels of proinflammatory genes, but not lipogenic genes,
tended to be lower in Pla2g5tg/+ mice than in control mice
(Figure S6F). After 6 weeks of HFD feeding, when the induc-
tion of endogenous Pla2g5 was still minimal (Figure S1B),
Fabp4-Pla2g5tg/+ mice displayed better insulin sensitivity and
lower WAT expression of Ccl2 compared to control mice (Fig-
ures S6G and S6H). Collectively, the data for adipocyte-spe-
cific PLA2G5 overexpression reciprocated those for PLA2G5
deficiency.
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Pla2g2e–/– Mice
To address the roles of PLA2G2E, we generated Pla2g2e–/– mice
(Figures S7A and S7B). Expression of mRNA and protein for
PLA2G2E was absent in WAT of HFD-fed Pla2g2e–/– mice (Fig-
ure S7C). On a HFD, obesity and weight gain tended to be lower
(though statistically insignificant) in Pla2g2e–/– mice than in
Pla2g2e+/+ mice (Figures 6A and 6B). Volumes of total, visceral,
and subcutaneous fats (Figure 6C) and adipocyte size in perigo-
nadal WAT (Figure 6D) were significantly reduced in HFD-fed
Pla2g2e–/–mice relative toPla2g2e+/+mice. Plasma leptin and in-
sulin levels (Figures S7DandS7E), glucose and insulin tolerances
(Figures S7F and S7G), food intake, locomotion and oxygen con-
sumption (Figures S7H–S7J), and WAT expression of adipoge-
nenic, lipogenic, lipolytic, and inflammatory genes (Figure S7K)
did not differ between HFD-fed Pla2g2e+/+ and Pla2g2e–/–
mice. HFD-induced fatty liver was mildly ameliorated by
PLA2G2E deficiency, as revealed by reductions of hepatic lipid
deposition (Figures 6E and6F), plasmaALT, and aspartate amino
transferase (AST) levels (Figure 6G), and hepatic expression of
some genes for lipid storage and inflammation (Figure S7L) in
HFD-fedPla2g2e–/– mice compared toWT littermates. Lower he-
patic Lpl expression in Pla2g2e–/– mice (Figure S7L) might partly
contribute to the reduced fat uptake into the liver.
HFD-induced increases in plasma phospholipids and
cholesterol were lower in Pla2g2e–/– mice than in Pla2g2e+/+
mice (Figure 6H), suggesting that PLA2G2E alters lipoprotein
composition. Indeed, phospholipids, TG, and cholesterol in
VLDL, LDL, and HDL were significantly lower in HFD-fed
Pla2g2e–/– mice than in Pla2g2e+/+ mice (Figures 6I and S7M).
ESI-MS revealed that LDL (Figure 6J) and HDL (data not shown)
in Pla2g2e–/– mice contained more PE and PS species, with no
apparent fatty acid selectivity, than those in Pla2g2e+/+ mice,
while PC species did not differ in both genotypes, suggesting
that adipocyte-derived PLA2G2E acts on PE and PS in favor of
PC in lipoproteins. The increase of these minor phospholipids
by PLA2G2E deficiency may eventually decrease the relative
proportion of PC and other lipids in lipoproteins, thereby
affecting lipid partitioning among tissues.
Taken together, PLA2G5 is protective against metabolic disor-
ders by hydrolyzing PC in hyperlipidemic LDL to release unsatu-
rated fatty acids, which attenuate adipose tissue inflammation
through M2 macrophage skewing, while PLA2G2E mildly pro-
motes adiposity and fatty liver by altering the proportion of PE
and PS in lipoproteins (Figure 7).
DISCUSSION
Adipocyte hypertrophy results in secretion of bioactive factors
such as adipokines, chemokines, and free fatty acids, which
adversely affect inflammation and tissue remodeling while
providing valuable protection against lipotoxic effects of excess
lipid exposure (Despre´s and Lemieux, 2006). We now show that
two particular sPLA2s are induced in hypertrophic adipocytes
and play distinct roles in metabolic control in the context of
diet-induced obesity. Our results add the sPLA2 family to a
growing list of extracellular lipolytic enzymes that cancontrol sys-
temicmetabolic states andgive another insight into the paracrine
role of sPLA2 in response to a given microenvironmental cue.The obesity-driven induction of PLA2G5 in hypertrophic
adipocytes, along with its constitutive expression at relatively
high levels in the heart and skeletal muscle, which have a high
demand for lipid as an energy source, suggests that one of the
primary roles of this sPLA2 may be related to the regulation of
energy metabolism. We show here that Pla2g5 ablation exacer-
bates diet-induced obesity, hyperlilidemia, and insulin resis-
tance, providing insight into the beneficial role of PLA2G5 in
metabolic disorders. PLA2G5 can hydrolyze PC in lipoproteins
in vitro (Sato et al., 2008), and our present results show that
this reaction does occur in vivo in the context of obesity, where
adipocyte-driven PLA2G5 hydrolyzes excess PC in lipid-over-
laden LDL, eventually protecting from hyperlipidemia. In this
regard, the metabolic effects of PLA2G5 are similar to those of
lipoprotein lipase, whose expression also shows a reciprocal
relationship with obesity-related traits (Chen et al., 2008). Even
though it has been thought that mice are not always good
models to study LDL metabolism, as they use VLDL and HDL
primarily, our results show that LDL metabolism by sPLA2 can
influence systemic metabolic states. The increased LDL-TG
levels and the reduced physical activities in Pla2g5/ mice
could impact adipocyte hypertrophy, hepatic steatosis, and
WAT inflammation. Importantly, PLA2G5 expression in human
WAT inversely correlates with plasma LDL levels, implying a hu-
man relevance of our observations. Moreover, our findings are
also compatible with the association of PLA2G5 mutations
with LDL levels in subjects with type 2 diabetes or obesity (Ser-
gouniotis et al., 2011; Wootton et al., 2007).
Importantly, PLA2G5 plays an anti-inflammatory role in
obesity, which likely makes a major contribution to the
exacerbated obesity, insulin resistance, and hyperlipidemia in
Pla2g5/ mice. This action of PLA2G5 depends on its capacity
to hydrolyze phospholipids in LDL to release unsaturated fatty
acids, which can allow the polarization shift of macrophages
from the M1 to M2 state. Reportedly, fatty acids released from
lipoproteins by venom sPLA2 or lipoprotein lipase can facilitate
anti-inflammatory responses in vitro (Ahmed et al., 2006; Duncan
et al., 2010; Namgaladze et al., 2010). Herein, we demonstrate
that unsaturated fatty acids including OA > LA, which are sup-
plied by PLA2G5-driven hydrolysis of PC in hyperlipidemic
LDL, prevent PA-induced M1 macrophage polarization, likely
through attenuating the ER stress, revealing a functional link
between lipoprotein metabolism and anti-inflammation by this
sPLA2. This mechanism fits with the view that PLA2G5 displays
an apparent (even if not strict) substrate preference for PC
bearing a fatty acid with a low degree of unsaturation. Our study
provides in vivo evidence that sPLA2 acts in this manner, thus
providing a rationale for the long-standing question on the phys-
iological importance of lipoprotein hydrolysis by this enzyme
family and revealing an anti-inflammatory mechanism exerted
by a particular sPLA2. Nonetheless, it cannot be fully ruled out
that the mobilization of PGE2, a u6 AA-derived eicosanoid that
promotes M2 macrophage skewing (Heusinkveld et al., 2011),
or u3 PUFA metabolites, which are protective against metabolic
disorders (Oh and Olefsky, 2012; Spite et al., 2014), might also
partly underlie the antiobese action of PLA2G5.
As another intriguing feature of PLA2G5, we show that it
is a ‘‘Th2/M2-prone sPLA2’’ that allows the immune balance
shift toward the Th2/M2 status. Given the increased metabolicCell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc. 127
Figure 6. Altered Diet-Induced Adiposity, Fatty Liver, and Lipoproteins in Pla2g2e–/– Mice
(A) Representative photos of Pla2g2e+/+ and Pla2g2e–/– mice fed a LFD or HFD.
(B) Body weights of Pla2g2e+/+ and Pla2g2e–/– mice fed a LFD or HFD for the indicated periods.
(legend continued on next page)
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Figure 7. Schematic Diagram of the Roles of Metabolic sPLA2s
In obesity, PLA2G2E is induced in adipocytes in accordance with adipo-
genesis and hydrolyzes PE and PS in VLDL, LDL, and HDL, eventually pro-
moting fat storage in WAT and liver. Subsequently, obesity-associated stress
induces PLA2G5 in hypertrophic adipocytes. PLA2G5 hydrolyzes PC in hy-
perlipidemic LDL and facilitates the skewing of macrophages from M1 to M2
subsets, thereby playing protective roles against adipose tissue inflammation,
insulin resistance, obesity, fatty liver, and hyperlipidemia. Saturated fatty acids
(e.g., palmitate) supplied abundantly from adipocytes trigger M1 polarization
of macrophages, which is ameliorated by PLA2G5-driven unsaturated fatty
acids (oleate > linoleate) from LDL or possibly some lipid mediators from
macrophages. It remains unknown whether particular PLA2G2E-produced
lipid mediator(s) would participate in this process.
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Il33, Stat6, or Pparg) (Odegaard and Chawla, 2013), the lack of
PLA2G5 may also decrease the whole-body Th2-M2 status,
thereby aggravating obesity-related inflammation. This notion
agrees with the fact that Pla2g5/ mice are resistant to asthma
(Giannattasio et al., 2010; Henderson et al., 2013), where Th2
cells and M2 macrophages promote allergy, while they suffer
from exaggerated arthritis or infection (Balestrieri et al., 2009;
Boilard et al., 2010), where Th2 immunity counteracts Th1/
Th17-based inflammation, thus accounting for the pro- versus
anti-inflammatory actions of PLA2G5 in distinct immunopatho-
logical settings. As the phagocytotic activities are distinct among
macrophage subsets (Leidi et al., 2009; Titos et al., 2011), the
altered M1/M2 ratio of macrophages in obese Pla2g5–/– WAT
could explain the perturbed clearance of dead cells. This idea
also accords with the finding that Pla2g5 ablation decreases
macrophage uptake of exogenous materials (Balestrieri et al.,
2009; Boilard et al., 2010).
We also show the in vivo role of PLA2G2E as another obesity-
induced, adipocyte-derived sPLA2. In contrast to PLA2G5 that(C) CT analysis of fat volumes in Pla2g2e+/+ and Pla2g2e–/– mice. Pink and yellow
(inset).
(D and E) Hematoxylin and eosin staining of WAT (D) or liver (E) from Pla2g2e+/+
(F and G) Levels of hepatic TG (F) and plasma ALT and AST (G) in Pla2g2e+/+ an
(H) Plasma levels of phospholipids (PL) and cholesterol (Chol) in Pla2g2e+/+ and
(I) PL, TG, and Chol levels in lipoproteins from HFD-fed Pla2g2e+/+ and Pla2g2e–
(J) ESI-MS of PC, PE, and PS in LDL from HFD-fed Pla2g2e+/+ and Pla2g2e–/– m
Mice were fed a LFD or HFD for 16 (A and C) or 18 (D–J) weeks. Data are compiled
two experiments are shown (A, D, and E). Mean ± SEM; *p < 0.05, **p < 0.01.hydrolyzes PC in LDL, PLA2G2E acts on PE and PS in VLDL,
LDL, and HDL. As such, PLA2G2E alters lipid composition in
lipoprotein particles, eventually moderately facilitating fat depo-
sition in tissues. Although little is known about the role of PE or
PS in lipoproteins, our study has shed light on the importance
of these minor lipoprotein phospholipids in the metabolic regu-
lation and opened an opportunity to analyze this issue using
Pla2g2e/ mice as a tool. As the increase of negative charges
in lipoproteins by oxidative modification renders the particles
smaller (Hidaka et al., 2005), the increase of anionic phospho-
lipids (e.g., PS) in lipoproteins may afford a similar effect. Lipo-
proteins with increased negative charges are more susceptible
to hydrolysis by hepatic lipase, resulting in smaller particles
(Boucher et al., 2007). Anionic phospholipids decrease the affin-
ity of ApoE for its receptor, thereby reducing lipid transfer into
tissues (Yamamoto and Ryan, 2007). Alternatively, Lyso-PE or
Lyso-PS produced by PLA2G2E might have some metabolic
effects, a possibility that needs to be addressed. Compatible
with our present study, PLA2G2A in place of PLA2G2E is
induced in obese rats in which the metabolic symptoms are
blocked by a PLA2G2A inhibitor (Iyer et al., 2012).
In summary, our study underscores the physiological rele-
vance of lipoprotein hydrolysis by sPLA2s, highlights metabolic
sPLA2s as integrated regulators of immune and metabolic re-
sponses, and brings about a shift toward a better understanding
of the biological roles of this extracellular lipolytic enzyme family
as a metabolic coordinator. The contrasting metabolic effects
of PLA2G5 and PLA2G2E are reminiscent of distinct roles
of PLA2G5 and PLA2G2A in arthritis (Boilard et al., 2010),
PLA2G5 and PLA2G10 in atherosclerosis (Ait-Oufella et al.,
2013; Bostrom et al., 2007), or PLA2G2D and PLA2G5 in anti-
gen-presenting cells (Giannattasio et al., 2010; Miki et al.,
2013), warning about the use of pan-sPLA2 inhibitors for therapy
and pointing to an alternative strategy to use a sPLA2 inhibitor
specific for individual sPLA2s. Targeting the metabolic sPLA2s
and their organ expression will be a challenge, since these en-
zymes appear to play highly selective roles in specific organs
and disease states.EXPERIMENTAL PROCEDURES
Mice
Pla2g5–/– (Satake et al., 2004), Pla2g5tg/+ (Ohtsuki et al., 2006), and their litter-
mate control mice were backcrossed onto the C57BL/6 mice (Japan SLC)
for >12 generations. Generation of Pla2g2e/ mice is detailed in Supple-
mental Information. Lepob/ob mice and Fabp4-Cre transgenic mice were ob-
tained from Jackson Laboratory. All mice were housed in climate-controlled
(23C) pathogen-free facilities with a 12 hr light-dark cycle, with free access
to standard LFD (CE2; CLEA Japan) and water. Knockout and littermate WT
mice (8-week-old female) were placed on a HFD (High fat diet 32; CLEA Japan)areas indicate visceral and subcutaneous fats in HFD-fed mice, respectively
and Pla2g2e–/– mice (scale bar, 50 mm).
d Pla2g2e–/– mice.
Pla2g2e–/– mice.
/– mice (n = 5).
ice.
from two (H–J) or three (B, C, F, and G) experiments. Representative images of
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Metabolic sPLA2s in Obesityor LFD for appropriate periods. All procedures were performed in accordance
with approvals by the Institutional Animal Care and Use Committees of Tokyo
Metropolitan Institute of Medical Science, Showa University, and the Univer-
sity of Washington.
Quantitative RT-PCR
Total RNA was extracted from tissues using TRIzol reagent (Invitrogen). First-
strand cDNA synthesis was performed using a High Capacity cDNA Reverse
Transcriptase Kit (Applied Biosystems). PCR reactions were carried out using
a Power SYBR Green PCR system (Applied Biosystems) or a TaqMan Gene
ExpressionSystem (AppliedBiosystems)on theABI7300RealTimePCRsystem
(AppliedBiosystems).Theprobe/primer setsusedare listed inTablesS3andS4.
Microarray
Total RNA was extracted from WAT derived from female C57BL/6 mice fed a
LFD or HFD for 18 weeks and purified using the RNeasyMini Kit (QIAGEN). The
quality of RNA was assessed with a 2100 Bioanalyzer (Agilent Technologies).
Both cDNA and cRNA were synthesized with a Low Input QuickAmp Labeling
Kit according to the manufacturer’s protocol (Agilent Technologies). Samples
were hybridized to the Whole Mouse Genome Microarray Kit (43 44K; Agilent
Technologies), washed, and then scanned using a SureScan Microarray
Scanner (Agilent Technologies). Microarray data were analyzed with Feature
Extraction software (Agilent Technologies) and then imported into GeneSpring
GX software (Agilent Technologies). Probes were normalized by quantile
normalization among all microarray data.
Flow Cytometry
The isolated SVF cells were incubated with either labeledmonoclonal antibody
or isotype control antibody (hamster IgG [HTK888], rat IgG2a [RTK2758], or rat
IgG2b [RTK4530]; BioLegend) and analyzed by flow cytometry with a FACSAria
III (BDBiosciences) and FlowJo (Tree Star) software. The antibodies usedwere
specific for mouse F4/80 (BM8; BioLegend), CD11b (M1/70; BioLegend),
CD11c (N418; eBioscience), and CD206 (C068C2; BioLegend).
Glucose and Insulin Tolerance Tests
Mice were fasted for 16 and 6 hr before intraperitoneal injection of glucose
(2 mg glucose/g body weight) (Wako) and insulin (0.75 mIU/g body weight)
(Eli Lilly) in saline, respectively. Blood glucose concentrations were monitored
at various time intervals using a Medisafe-Mini blood glucose monitoring sys-
tem (Terumo).
Measurement of Serum Biomedical Markers
Serum insulin and leptin levels were quantified by a mouse insulin ELISA kit
(Mercodia) and a leptin immunoassay kit (R&D Systems), respectively. Serum
ALT and AST levels were quantified using the transaminase CII-test Wako kit
(Wako).
CT Analysis
Mice were anesthetized with nembutal (0.5 mg/g body weight) (Dainippon
Sumitomo Pharma), and their adiposity was analyzed using the micro-CT sys-
tems eXplore Lucus Micro CT Scanner (GE Healthcare) or Latheta LCT-100
(Aloka).
Oxygen Consumption and Locomotor Activity
Oxygen consumption was measured every 3min over 24 hr under resting con-
ditions using an MK-5000RQ metabolism measuring system for small animals
(Muromachi Kikai). For measurement of basal locomotor activity, mice were
placed into chambers of an ACTIMO-S food intake, drinking, and locomotor
activity monitoring system (Shintechno). Food and water were provided ad
libitum. Mice were allowed to acclimatize in the chambers for 24 hr, and
then their physical activities were measured over the next 24 hr.
Analyses of Plasma Lipids and Lipoproteins
Analysis of plasma lipoproteins was performed by LipoSearch (Skylight
Biotech). Plasma cholesterol, phospholipid, LPC, TG, and NEFA levels were
determined with a Determinar TC2 (Kyowa Medex), a Phospholipid C Test
(Wako), a LPC Assay kit (AZWELL), a Determinar TG2 (Kyowa Medex), and a
NEFA C Kit (Wako), respectively.130 Cell Metabolism 20, 119–132, July 1, 2014 ª2014 Elsevier Inc.ESI-MS/MS
Lipid analysis was performed using a 4000 QTRAP quadrupole-linear ion trap
hybrid MS (AB SCIEX) with liquid chromatography (LC-20AP; Shimazu) com-
bined with a HTS PAL autosampler (CTC Analytics AG), as detailed in Supple-
mental Information.
Cell Culture Studies
Studies using adipocytes and immune cells are detailed in Supplemental
Information.
Human Samples
Mesenteric WAT and fatty appendices were obtained by curative resection
from 64 patients with colorectal tumors, all of whom underwent elective
surgical colorectomy at the Kumamoto University Hospital (Kumamoto, Japan)
from March 1, 2012 to August 31, 2013. The clinical characteristics are sum-
marized in Table S2. The study was approved by the Ethics Committees of
Kumamoto University, with written informed consent from all patients.
Statistical Analyses
All values are given as themean ± SEM. Differences between two groups were
assessed by using the unpaired two-tailed t test. Data involving more than two
groups were assessed by ANOVA, and relationships between clinical and
metabolic parameters were assessed by Spearman’s rank correlation test.
Correlation coefficients (R) and probability (P) values were calculated with
the Excel Statistical Program File yStat 2008 (Igaku Tosho Shuppan).
ACCESSION NUMBERS
The GEO accession number for microarray data reported in this paper is
GSE56038.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.cmet.2014.05.002.
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